Blueprint Medicines (BPMC) Misses Q4 EPS by 12c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Blueprint Medicines (BPMC) PT Raised to $98 at Wedbush
February 22, 2018 3:28 PM ESTWedbush raised its price target on Blueprint Medicines (NASDAQ: BPMC) to $98.00 (from $96.00) while maintaining a Outperform rating.
Analyst David Nierengarten commented, "In addition to working toward enrollment of the registration-directed PDGFR-driven GIST trial set to complete mid-year, BPMC has moved... More
